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Background: Early identification and treatment of individuals with autism spectrum
disorder (ASD) improves outcomes, but specific evidence needed to individualize
treatment recommendations is lacking. Biomarkers that could be routinely measured
within the clinical setting could potentially transform clinical care for patients with
ASD. This demonstration project employed collection of biomarker data during regular
autism specialty clinical visits and explored the relationship of biomarkers with clinical
ASD symptoms.
Methods: Eighty-three children with ASD, aged 5–10 years, completed a multi-
site feasibility study integrating the collection of biochemical (blood serotonin, urine
melatonin sulfate excretion) and clinical (head circumference, dysmorphology exam,
digit ratio, cognitive and behavioral function) biomarkers during routine ASD clinic
visits. Parents completed a demographic survey and the Aberrant Behavior Checklist-
Community. Cognitive function was determined by record review. Data analysis utilized
Wilcoxon two-sample tests and Spearman correlations.
Results: Participants were 82% male, 63% White, 19% Hispanic, with a broad range
of functioning. Group means indicated hyperserotonemia. In a single regression analysis
adjusting for race and median household income, higher income was associated with
higher levels of blood serotonin and urine melatonin sulfate excretion levels (p = 0.004
and p = 0.04, respectively). Melatonin correlated negatively with age (p = 0.048) and
reported neurologic problems (p = 0.02). Dysmorphic status correlated with higher
reported stereotyped behavior (p = 0.02) and inappropriate speech (p = 0.04).
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Conclusion: This demonstration project employed collection of multiple biomarkers,
allowed for examination of associations between biochemical and clinical measures, and
identified several findings that suggest direction for future studies. This clinical research
model has promise for integrative biomarker research in individuals with complex,
heterogeneous neurodevelopmental disorders such as ASD.
Keywords: autism, ASD, biomarkers, serotonin, melatonin, dysmorphology, clinical research
INTRODUCTION
Autism spectrum disorder (ASD) is a highly heritable,
heterogeneous neurodevelopmental disorder characterized
by impaired social interaction and communication as well as
restricted, repetitive behavior presenting in early childhood
(American Psychiatric Association and DSM-5 Task Force,
2013). There is no curative treatment for ASD, but early
intensive behavioral treatment can significantly improve
long-term developmental outcomes (Lord and Mcgee, 2001;
Estes et al., 2015; Reichow et al., 2018). However, specific
measures needed to individualize treatment recommendations
are lacking. Biomarkers could potentially identify clinically
meaningful subgroups within highly heterogeneous populations
and thus allow for more precise, individualized medical care
by identifying risk, confirming diagnosis or guiding response
to treatments (National Research Council, 2011; Veenstra-
VanderWeele and Blakely, 2012; Insel, 2014; Interagency Autism
CoordinatingCommittee [IACC], 2014; Ruggeri et al., 2014;
De Los Reyes and Aldao, 2015; Varcin and Nelson, 2016).
Recent authors have advocated for simultaneous measurement
of multiple biomarkers to inform the understanding of the
numerous systems and complex interactions that are likely to be
involved in heterogeneous conditions (Hammock et al., 2012;
Schendel et al., 2012; Ruggeri et al., 2014).
An extensive body of research is emerging on potential
biomarkers in ASD including genetic, biochemical, proteomic,
metabolomic, immune and redox markers as well as
neuroimaging, electrophysiologic, physical and behavioral
characteristics (Wang et al., 2011; Frustaci et al., 2012;
Tordjman et al., 2013; Gabriele et al., 2014; Ruggeri et al.,
2014; Varcin and Nelson, 2016).
Biochemical markers include neurotransmitters, hormones
and markers of immune function and inflammation. Studies
have consistently shown higher mean levels of platelet serotonin
in individuals with ASD compared to controls (Schain and
Freedman, 1961; Anderson et al., 1987; Cook and Leventhal,
1996; Mulder et al., 2004; Hammock et al., 2012; Gabriele
et al., 2014; Pagan et al., 2014). Prior studies have also shown
lower plasma levels of the pineal hormone melatonin and
overnight urinary excretion of its major metabolite, melatonin
sulfate, in individuals with ASD (Tordjman et al., 2005; Pagan
et al., 2014). These biochemical markers can also vary with
race, age, and gender (McBride et al., 1998; Duffy et al., 2011;
Hammock et al., 2012). For example, elevations in platelet
serotonin are particularly notable in prepubertal children with
ASD (McBride et al., 1998).
A small number of studies have examined relationships
between the chosen biomarkers and clinical characteristics in
children with ASD. Elevated platelet serotonin levels have been
associated in ASD with poorer speech development (Hranilovic
et al., 2007), impaired social communication and play skills
(Mulder et al., 2010), disruptive behavior (Kuperman et al.,
1987), self-injury (Kolevzon et al., 2010), and higher autism
severity (Abdulamir et al., 2018). Reduced urinary melatonin was
associated with impaired social communication and play skills in
ASD (Tordjman et al., 2012), and with higher serotonin levels
(Mulder et al., 2010). Physical features such as macrocephaly,
lower 2D:4D ratio and dysmorphic features are more common
in individuals with ASD compared to controls and may correlate
with symptom severity including lower IQ, language deficits
and comorbid seizures (Courchesne et al., 1999, 2011; Manning
et al., 2001; Miles et al., 2005; Sacco et al., 2007; Schaefer
and Mendelsohn, 2008; Miller et al., 2010; Honekopp, 2012).
Given the high rates of co-occurring conditions such as GI
problems, sleep problems and seizures in ASD, studies examining
the relationships of these conditions to biomarkers of interest
could further inform understanding of subpopulations within the
autism spectrum (Aldinger et al., 2015; Kohane, 2015).
Recently, studies have examined correlations between
biomarkers or assessed more than one biomarker simultaneously
(Sacco et al., 2010; Hammock et al., 2012; Schendel et al.,
2012; Pagan et al., 2014; Ruggeri et al., 2014). For example,
Hammock and colleagues found that oxytocin and serotonin
were inversely related in individuals with ASD (Hammock
et al., 2012). Pagan and colleagues examined associations of
biomarkers with autism severity and clinical symptoms (e.g.,
melatonin with sleep disruption) and found that combined
analysis of serotonin, N-acetylserotonin and melatonin levels in
individuals differentiated individuals with autism from controls
with 80% sensitivity and 85% specificity (Pagan et al., 2014).
Sacco and colleagues collected information on a number of
clinical traits in a study population and identified clusters of
phenotypes (Sacco et al., 2010). The SEED study, a large national
epidemiologic study of individuals with ASD and controls, is
gathering data on multiple biomarkers and clinical characteristics
(Schendel et al., 2012).
These types of studies can help elucidate potential etiologic
pathways, distinguish cases from controls and identify subgroups
of patients who may be phenotypically similar. One limitation
of prior research, however, has been small sample sizes and
participation bias. Identification of biomarkers that could be
measured within the clinical setting would target large numbers
of participants and potentially transform clinical care for patients
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with ASD (Hammock et al., 2012). Relatively few biomarkers,
however, have been studied systematically in children with
ASD, and the cost and feasibility of biomarker measurement
varies. For example, neurophysiological biomarkers such as EEG
require specialized equipment and staff training and cannot
be easily completed during a regular follow-up clinic visit
(Varcin and Nelson, 2016).
The clinical setting remains a relatively untapped resource for
investigation of neurodevelopmental disorders including ASD
for several reasons, among them differing priorities between
clinical care and research, practical challenges including limited
research infrastructure and cultural and attitudinal barriers in
many clinical settings. Additionally, the specific core features of
ASD such as sensory sensitivity and behavioral rigidity present
barriers for individuals to participate in research.
To address these challenges, we conducted a multi-site
demonstration project that evaluated the feasibility of integrating
collection of biomarker and clinical data during ASD specialty
clinic visits (Sices et al., 2017). Our primary hypotheses related
to feasibility of the research model and we found that individuals
with a range of developmental and behavioral functioning were
able to participate and that the study activities did not interfere
with clinical care. As part of the study, we collected multiple
biomarkers on each participant to maximize the information
collected in conjunction with a scheduled clinical visit (as
opposed to a separate research visit). Our approach to assessment
of correlations between biomarkers was exploratory. The chosen
biomarkers, platelet serotonin and urinary melatonin sulfate,
head circumference, dysmorphic status, and ratio of second and
fourth digits (2D:4D), had prior evidence of association with
ASD and could be measured with relative ease, efficiency and
economy across multiple sites (Honekopp, 2012; Schendel et al.,
2012; Teatero and Netley, 2013; Ruggeri et al., 2014; Mackus et al.,
2017; Paynter et al., 2018).
This paper describes the range for platelet serotonin, urinary
melatonin sulfate, head circumference, dysmorphic status and
2D:4D ratio in our clinical study population. In addition,
this paper explores potential relationships among individual
biomarkers, demographic features including sex, socioeconomic
status (SES), and clinical features including cognitive level,
behavioral function and co-morbid medical symptoms.
MATERIALS AND METHODS
Participants
We recruited participants from five academic medical centers in
Massachusetts that specialize in ASD assessment and treatment.
Recruitment and classification procedures have been described
previously (Sices et al., 2017). This study was approved
by the Institutional Review Board at the lead site (Boston
Children’s Hospital).
Children between 5 and 10 years old with a prior clinical
diagnosis of ASD and scheduled for a regular clinic follow-up
visit between April 2014–May 2015 at one of the five research
sites were eligible to participate in the study. ASD diagnoses were
verified by the children’s clinicians, all of whom were pediatric
specialists with expertise in the diagnosis and treatment of ASD
(developmental behavioral pediatricians, pediatric neurologists,
nurse practitioners, and child psychiatrists). Participants’ ages
were limited to between 5 and 10 years to improve stability of
the ASD diagnosis and to increase the likelihood of pre-pubertal
status, as some biomarkers vary with puberty.
Only one child per family was enrolled in the study. Exclusion
criteria included having a non-English speaking caregiver or
taking medication that could affect serotonin or melatonin
metabolism within 2–6 weeks of the study visit (Supplementary
Table 1). There were no exclusions for epilepsy, language
impairment, level of intellectual functioning, or known genetic
syndrome. Prior to conducting study activities, written informed
consent was obtained from the participant’s legal guardian and
informed assent was elicited from children age 7 years and
older, who were able.
Data/Sample Collection Measures
Parents/guardians completed a demographic and medical history
form including birth history, medications, co-morbid medical
symptoms, and family medical history. Parents/guardians
also completed the Aberrant Behavior Checklist-Community
(ABC-C), a 58-item behavioral functioning measure for
children and adults with developmental disabilities that includes
five subscales: irritability and agitation; lethargy and social
withdrawal; stereotypic behavior; hyperactivity and non-
compliance; and inappropriate speech (Aman et al., 1985).
Scoring was completed using the method validated for children
with ASD (Kaat et al., 2014).
Research staff reviewed medical records for each participant
to identify results of the most recent cognitive testing
(developmental or IQ test results). To allow for comparison
amongst the various developmental and intellectual assessment
measures documented across all participants, only non-verbal
cognitive scores (Bayley cognitive score or non-verbal IQ) were
analyzed. Study data were collected and managed using REDCap
(Research Electronic Data Capture), a secure, web-based
application for electronic data capture hosted at the lead site.
We estimated household income based on participant zip code
as a proxy for SES. We assigned the median income reported
in the 2012 U.S. Census for each participant’s zip code. Zip
code regions were assigned to a quintile based on the national
breakdown of income distribution (Geronimus and Bound, 1998;
U.S. Department of Commerce, 2013).
As a part of each participant’s clinic visit, clinicians or their
clinical staff obtained measurements of head circumference,
height and weight. Clinicians then recorded results of a
standardized dysmorphology examination (Miles et al., 2008;
Sices et al., 2017). Photocopies of each participant’s hands were
obtained by study staff following the clinic visit to provide 2D:4D
ratios using established methodology (Manning et al., 1998).
Photocopies that were not clear or did not demonstrate clear
markings of the digits were omitted from analysis.
A 3 mL EDTA-anticoagulated whole blood sample was
obtained from each participant for platelet count and
serotonin analysis. Automated platelet count measurements
were performed locally at each respective study site within
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24 h of collection. Aliquots of whole blood were stored
at −80◦C until shipment on dry ice to the Anderson
research laboratory at Yale University for platelet (whole
blood) serotonin measurement, using previously published
methodology (Anderson et al., 1987; Epperson et al., 2001).
Overnight urine sample was collected for melatonin sulfate
and creatinine analyses either from a first morning void, or an
overnight diaper, thus representing nighttime production of
melatonin for all samples. Urine samples were similarly stored
at −80◦C until shipment on dry ice to the Anderson laboratory.
Melatonin sulfate-like immunoreactivity was measured by
ELISA kit provided by IBL International (Toronto, ON, Canada)
and creatinine levels were determined by HPLC using UV
absorbance detection (240 nm) following 10-fold dilution
(Hausen et al., 1981).
Statistical Analysis and Considerations
Wilcoxon two-sample tests were used throughout to test for
differences between groups of participants with and without a
given characteristic. Spearman correlations were computed to
estimate correlation between two continuous variables. Income
was analyzed as a continuous variable. Race was challenging to
analyze due to the small number of participants endorsing some
racial categories, the number of participants selecting more than
one category and the number selecting only the ‘Other’ category,
which was not further specified. Linear regression models were
used to test for effects of race and median household income
on the two primary biomarker outcomes (platelet serotonin and
urinary melatonin sulfate). A p-value < 0.05 was used as a cut-
off for statistical significance. All tests were two-sided. Due to the
exploratory nature of the study, no adjustments were made for
multiple comparisons (Rothman, 1990).
RESULTS
A total of 88 participants were enrolled in the study; five
were subsequently excluded from data analysis resulting in an
analyzable sample of 83. Of the five excluded individuals, two
did not provide at least one sample for biochemical measurement
(blood for platelet serotonin or urine for melatonin sulfate
excretion), two were discovered to be taking medications not
disclosed at time of enrollment [fluoxetine (n = 1) and melatonin
(n = 1)], and one voluntarily withdrew from the study.
Group Descriptive Statistics
Demographics
Participant demographics are summarized in Table 1. The mean
age of participants was 7.4 ± 1.6 years and 82% were male.
Participants identified race and ethnicity by checking as many
categories as applied. Overall, 63% endorsed White only, 7%
Black only, 5% Asian only, 13% endorsed more than one racial
category and 14% endorsed an “Other” category that was not
further specified. Nineteen percent endorsed Hispanic ethnicity.
Mean average income (estimated from zip code of residence)
was $57,700 (SD 19,800), with a range from $26,944 to $121,693
across all participants (Table 1).
TABLE 1 | Demographics and characteristics of study participants.
Sex n (%)
Female 15 (18%)
Male 68 (82%)
Race∗ n (%)
Single Race 72 (87%)
American Indian/Alaskan Native 0 (0%)
Asian 4 (5%)
Black/African American 6 (7%)
Other 10 (12%)
White/Caucasian 52 (63%)
Multiple Races 11 (13%)
Black and American Indian/Alaskan 1 (1%)
Black and White 5 (6%)
White and American Indian/Alaskan 1 (1%)
White and Asian 1 (1%)
White and Black and American Indian/Alaskan 1 (1%)
White and Other 2 (2%)
Ethnicity n (%)
Hispanic 16 (19%)
Non-Hispanic 66 (80%)
Unknown 1 (1%)
Age Mean (SD)
Age at diagnosis (years) 3.2 (1.6)
Age at visit (years) 7.4 (1.6)
Income∧ Mean (SD), Median
Income of participant’s zip code $57.7K ($19.8K), $55.6
Cognitive Function N, Mean (SD)
Non-verbal cognitive score 50, 88 (19)
ABC-C#Checklist Subscale Score (n = 81) Mean (SD)
Irritability 13.5 (9.9)
Withdrawal 11.2 (7.8)
Stereotypy 5.5 (4.6)
Hyperactivity 15.3 (8.8)
Inappropriate Speech 4.7 (3.4)
Genetic Testing N (%)
Had Genetic Testing Reported 58 (70%)
Known Genetic Syndrome 1 (%)
Variant of Unknown Significance 7 (%)
∗Participants could endorse any applicable race; all responses tallied. #Aberrant
Behavior Checklist – Community. ∧Based on U.S. Census data from
the 2012 Census.
Developmental Function
ABC-C score distributions for the study group were comparable
with recently published norms for children with ASD and
represented a range of behavioral function (Kaat et al., 2014).
Cognitive test results were available for 65 participants (78%).
Mean age at cognitive testing was 5.4 years (SD = 2.2 years). Mean
time elapsed from date of cognitive testing to date of biomarker
sample collection was 2.3 years (SD = 1.8 years). Reported non-
verbal standard scores ranged from 43 to 121 (mean = 88,
SD = 19) with 14% having a non-verbal cognitive score below 70.
Genetic testing results were reported for 58 patients. Of those,
1 had a genetic syndrome and 7 had a variant of unknown
significance (Table 1).
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Biomarkers
Discussion of study activity completion rates and feasibility has
been previously described (Sices et al., 2017). Mean values and
standard deviations as well as completion/collection rates for
each of the biomarkers are shown in Table 2.
Biochemical Markers
The serotonin and urinary melatonin sulfate excretion measures
were non-normally distributed (Shapiro–Wilk tests, all
p-values < 0.001). Mean levels for platelet serotonin in our
participant group were elevated from previously published
norms (McBride et al., 1998) consistent with the presence of
hyperserotonemia. Urinary melatonin sulfate excretion rates
in our ASD participant group, however, were not lower than
prior reported rates in control populations (Tordjman et al.,
2005) (Table 2).
Age was negatively correlated with melatonin sulfate excretion
(r = −0.26, p = 0.048). We did not find an age association for
serotonin. Contrary to previously published results, we did not
identify a negative correlation between platelet serotonin and
melatonin sulfate excretion levels (r = −0.008, p = 0.95). In
addition, there were no correlations between platelet serotonin
and melatonin sulfate excretion levels and sex, ethnicity, non-
verbal cognitive level, or ABC-C subscale scores (Table 3).
Due to the limited numbers of participants endorsing certain
race categories we were not able to conduct comparative
analyses. We examined platelet serotonin level and melatonin
TABLE 2 | Biomarker completion rates and group mean values.
Measure N (%) completing
measure
Mean (SD) or N
(%) dysmorphic
Serotonin (ng/mL) 73 (88%) 236 (92)
Platelet serotonin (ng/billion
platelets)
71 (86%) 822 (407)
Urinary melatonin sulfate
(ng/mg creatinine)
71 (86%) 131 (78)
Head circumference
(z-score)
72 (87%) 0.77 (1.19)
2D:4D right hand 63 (76%) 0.96 (0.04)
2D:4D left hand 35 (42%) 0.96 (0.04)
Dysmorphology exam 75 (90%) 6 (8%)
excretion rate by household income. The bivariate correlation
of platelet serotonin and median household income was positive
but did not reach statistical significance (r = 0.20, p = 0.09).
In a single linear regression model testing for the effects
both of race and of median household income on platelet
serotonin, however, race and income were each independently
associated with platelet serotonin. Household income was
significantly associated with higher platelet serotonin levels
in this regression with mean platelet serotonin increasing
an estimated 9.8 points per $10K increase in household
income (p = 0.004).
Melatonin sulfate and median household income were
positively correlated (r = 0.25, p = 0.03) in bivariate analysis. In
the linear regression model, higher median household income
was associated with higher melatonin sulfate excretion levels with
an estimated increase of 13.8 ng/mg creatinine per $10K increase
in household income (p = 0.04).
Physical Markers
2D:4D values were consistent with prior reports showing ratios
for ASD participants below published norms (Manning et al.,
2001). Head circumference values had a mean z-score 0.77 with
range from −1.72 to 3.60. Twelve of the 72 participants (17%)
with head circumference measurements were macrocephalic (z-
score> 2SD). Dysmorphology examination was performed on 75
participants: 6 (8%) were identified as dysmorphic. Additionally,
42 of these participants (55%) had an abnormal finding in
one or more body regions with the most frequently identified
regions being the ear (20%), hair pattern (18%) and philtrum
(16%). Dysmorphic status did not correlate with report of
abnormal genetic test results. Only 3 of the 6 dysmorphic
participants had cognitive testing results, scores ranged from 70
to 100 (Table 2).
Co-occuring Conditions
Participants had high rates of caregiver reported co-occuring
medical and psychiatric conditions including: 52% with
gastrointestinal (GI) conditions, 40% with sleep problems,
41% with psychiatric conditions (including 25% with ADHD
and 5% with anxiety disorder), 31% with history of regression
in developmental skills, and 20% with neurologic conditions
(including 7% with seizures) (Table 4).
TABLE 3 | Biochemical markers by demographic characteristics.
Patient characteristics Platelet serotonin (ng/billion
platelets) n, mean (SD)
p-Value Urinary melatonin sulfate excretion
(ng/mg creatinine) n, mean (SD)
p-Value
Sex 0.10 0.20
Male 59, 852.5 (427.4) 58, 125.6 (77.9)
Female 12, 671.0 (245.6) 13, 152.6 (76.1)
Ethnicity 0.50 0.44
Hispanic 15, 732.9 (235.0) 14, 121.1 (72.2)
Other 56, 845.6 (440.3) 56, 134.3 (79.6)
Non-verbal IQ 0.28 0.29
Below 70 7, 1042.5 (657.2) 2, 144.0 (2.8)
70 or above 38, 800.3 (401.4) 40, 131.5 (79.0)
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TABLE 4 | Caregiver-reported comorbid conditions.
Condition N (%)
Neurodevelopmental/neurologic problems
Premature birth 11 (13%)
History of regression 26 (31%)
Neurologic conditions 17 (20%)
Seizures 6 (7%)
Headaches 2 (2%)
Sleep problems
Any sleep problem 33 (40%)
Difficulty going to bed 15 (18%)
Difficulty falling asleep 19 (23%)
Unusually tired/sleepy during the day 13 (16%)
Difficulty waking up 13 (16%)
Very long or frequent naps 6 (7%)
Frequent or prolonged awakenings at night 17 (20%)
Sleepwalking or frequent nightmares 5 (6%)
No regular bed time and wake time 13 (16%)
Gastrointestinal problems
Any GI condition 43 (52%)
Constipation 35 (42%)
Diarrhea 15 (18%)
Gastro-esophageal reflux disease (GERD) 10 (12%)
Psychiatric and behavioral conditions
Any psychiatric disorder 34 (41%)
Anxiety disorder 4 (5%)
OCD 1 (1%)
ADHD 21 (25%)
Disruptive behavior disorder 6 (7%)
Depressive disorder 1 (1%)
Mood disorder 1 (1%)
Self-injurious 3 (4%)
Pica 2 (2%)
Enuresis or encopresis 2 (2%)
Totals do not add up to 100% as some participants reported more than one
condition in each category. No caregivers reported schizophrenia or psychosis.
Correlations of Biochemical Measures
With Participant Characteristics
Biochemical Measures, Physical Characteristics, and
Behavioral Functioning
Platelet serotonin levels and melatonin sulfate excretion were not
significantly correlated with head circumference z-score, 2D:4D
ratio, or dysmorphology status. There were also no associations
among the physical measures (head circumference, 2D:4D, and
dysmorphology status). Patients with dysmorphic status scored
significantly higher than other patients on two of the ABC
subscales [stereotypic behaviors: 10.0 (SD: 4.0) vs. 5.1 (SD: 4.5),
p = 0.019; inappropriate speech 7.0 (SD: 2.9) vs. 4.5 (SD: 3.5),
p = 0.043].
Biochemical Markers and Co-occurring Conditions
We examined correlations between both urinary melatonin
sulfate excretion and platelet serotonin with co-occurring
conditions including GI and neurologic problems, seizures, and
sleep conditions reported by caregivers (Table 5). Patients with
neurologic conditions (n = 15) had lower melatonin sulfate
excretion than patients without these conditions [respectively:
mean (SD): 91.4 (42.5) vs. 145.7 (81.3), p = 0.02]. There was
no difference in mean age of participants with and without
neurologic conditions (p = 0.69). No association was found
between melatonin sulfate excretion and reported sleep problems
(Table 5). We identified a trend toward an association between
higher platelet serotonin levels and reported GI conditions
(medians: 778 vs. 702, p = 0.08) Three participants had platelet
serotonin values above 2000 ng/billion platelets (one was > 2
SD and the other two were > 3 SD above the mean); all three
participants endorsed GI symptoms.
DISCUSSION
In this pilot demonstration feasibility project, collection of
multiple biomarkers during a regularly scheduled ASD specialty
clinical visit allowed for the examination of associations between
biochemical and clinical measures, and identified several findings
that suggest direction for future studies. While our findings
for individual biochemical and clinical biomarkers should
not be viewed as definitive, we found associations between
platelet serotonin and melatonin sulfate excretion with patient
demographic and clinical characteristics that illustrate the
potential of this approach to generate important information
about multiple biomarkers and functional domains within a
single heterogeneous clinical patient population.
Consistent with prior research, we identified elevated platelet
serotonin levels in our sample, with means and ranges similar
to previously published data for children with ASD (McBride
et al., 1998; Mulder et al., 2004; Hammock et al., 2012). In
contrast to previous studies, urinary melatonin sulfate excretion
rates in our ASD participant group were not lower than prior
reported rates in control populations (Tordjman et al., 2005).
However, the limited available data on a similar age range and
using a similar analytical methodology limit comparison of the
melatonin sulfate results to prior reports. The overall racial
distribution and the high proportion of participants endorsing
more than one race precluded analysis of biomarker levels by
race. Unexpectedly, however, we found that higher income,
independent of race, was associated with higher platelet serotonin
and higher melatonin sulfate excretion. The reasons for this are
likely complex, as income estimated by zip code was used as a
proxy for SES and may reflect multiple social and environmental
factors including diet. Lower melatonin sulfate excretion was
associated with increasing age during childhood in our sample
as has been previously reported (Tordjman et al., 2005). In
contrast, we did not find an age-based variation in platelet
serotonin whereas prior studies found that serotonin levels
correlate negatively with age in children with ASD (McBride
et al., 1998; Hammock et al., 2012). This may be explained by
the narrow age range of our study. A more recent study did
not find an age-based difference in serotonin when comparing
individuals with ASD who were below 16 years with those at or
above 16 years (Pagan et al., 2014). Additionally, although a prior
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TABLE 5 | Mean and standard deviation (SD) for biochemical markers in patients with co-morbid medical conditions, and comparisons between participants endorsing
and not endorsing these conditions.
Co-morbid conditions Platelet serotonin (ng/billion platelets) Urinary melatonin sulfate (ng/mg creatinine)
n, Mean (SD) p-Value n, Mean (SD) p-Value
Gastrointestinal problem∗ 0.08 0.55
Yes 34, 934.3 (521.5) 36, 137.6 (86.4)
No 37, 718.4 (222.5) 34, 120.9 (67.7)
Neurologic problem∗ 0.85 0.02∗∗
Yes 14, 858.8 (568.8) 15, 91.4 (42.5)
No 52, 805.9 (372.5) 53, 145.7 (81.3)
Seizures∗ 0.85 0.12
Yes 5, 1068.2 (955.3) 4, 81.0 (46.7)
No 57, 798.8 (359.4) 60, 141.0 (78.5)
Any sleep problem 0.16 0.27
Yes 27, 761.4 (395.0) 29, 111.4 (61.0)
No 44, 858.9 (414.0) 42, 143.7 (85.7)
∗Participants endorsing “not sure” for Gastrointestinal (N = 1) or Neurologic problem (N = 6), or “suspected” or “not sure” for Seizures (N = 10) excluded from analysis.
∗∗Significant at p < 0.05.
study showed a negative correlation between platelet serotonin
and urinary melatonin (Mulder et al., 2010), the Pagan study did
not find this correlation in a multi-aged (children and adults)
sample of 230 patients with ASD (Pagan et al., 2014). Further
studies with detailed sociodemographic variables will be needed
to clarify these findings.
Frequencies of dysmorphic physical features in the study
sample were similar to prior published findings for children with
ASD. Dysmorphology examination identified six participants
(8%) as dysmorphic using the scoring algorithm described by
Miles et al. (2008). This compares to a rate of 12% reported
as dysmorphic by Miles for a population of patients with
autistic disorder. Of note, we did not preferentially select
patients from settings that would typically have higher levels of
dysmorphic features such as genetic specialty clinics. Although
we did not have sufficient power to examine the relationship
of dysmorphic status and cognitive functioning, dysmorphic
status was correlated with higher ratings on the ABC stereotypy
and inappropriate speech domains, suggesting higher symptom
severity. This is consistent with prior studies documenting that
patients with “syndromic autism” have more severe phenotypes
(Miles et al., 2005; Schaefer and Mendelsohn, 2008).
Caregiver reported frequencies of comorbid medical and
psychiatric conditions including developmental regression, sleep
problems, ADHD, GI symptoms, and seizures were similar
to those reported in other ASD cohorts (Richdale, 1999;
Goldberg et al., 2003; Lord et al., 2004; Polimeni et al.,
2005; Leyfer et al., 2006; Ibrahim et al., 2009; Buie et al.,
2010; Murray, 2010; Aldinger et al., 2015). Study participants
had lower levels of anxiety (5%) than previously reported
(Filipek et al., 2000; Myers and Johnson, 2007; Volkmar et al.,
2014), most likely explained by the study exclusion criteria
that restricted participants on medications known to influence
serotonin levels.
Serotonin [5-hydroxytryptamine (5-HT)] and melatonin are
important in neurogenesis, synaptogenesis, mood, sleep, and
GI function (Gabriele et al., 2014). Gastrointestinal symptoms
were reported by 51% of participants, consistent with prior
studies showing rates of GI symptoms ranging from 9 to 91%
in children with ASD (Molloy and Manning-Courtney, 2003;
Valicenti-McDermott et al., 2006; Ibrahim et al., 2009; Buie
et al., 2010). A recent meta-analysis reported an odds ratio
of 4.42 for GI problems in children with ASD (McElhanon
et al., 2014). We did not identify significant associations
between GI symptoms and platelet serotonin or melatonin
sulfate excretion. However, we did observe a trend-level
association between higher platelet serotonin and reported GI
symptoms. In addition, three participants who were outliers
with very high platelet serotonin (above 2000 ng/billion
platelets) all reported GI symptoms. This is consistent with
a recent study examining whole blood serotonin levels and
co-occurring GI symptoms in 82 children age 6–15 years
with ASD that identified a moderate positive correlation
(r = 0.23, p = 0.048) between GI symptom score and serotonin
levels in Caucasian participants (Marler et al., 2016). In
addition, specific serotonin-related gene variants in individuals
with ASD may contribute to gastrointestinal disturbance
(Abdelrahman et al., 2014). Future studies examining serotonin
levels in patients with ASD and co-occurring GI problems
appear warranted.
Melatonin sulfate excretion was negatively associated with
reported neurologic problems (p = 0.02), with much of
the association due to lower levels in participants reporting
diagnosed or suspected seizures. The rate of seizures (7%) was
lower than that reported for other populations of children and
adolescents with ASD. However, the age range of our study
participants was between the two peak onset periods for seizures
in ASD, early childhood and adolescence (Filipek et al., 2000;
Myers and Johnson, 2007). An analysis of medical conditions
in the AGRE and Simons Simplex Cohort (SSC) found similar
rates of seizures (12.2 and 5.3% respectively) in two cohorts
with mean age 9.2 and 9.0 years (Aldinger et al., 2015). Prior
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studies document lower melatonin secretion in individuals with
refractory epilepsy compared to controls, and elevated melatonin
levels following seizures; importantly, these studies did not
examine associations with ASD (Bazil et al., 2000; Yalyn et al.,
2006; Paprocka et al., 2010). Future studies examining urinary
melatonin sulfate excretion levels in individuals with ASD and
epilepsy would be of interest.
Variants in melatonin pathway genes have been associated
with sleep onset delay (Veatch et al., 2015) and melatonin
administration has been associated with improvements in sleep
in children with ASD (Doyen et al., 2011; Guenole et al., 2011;
Rossignol and Frye, 2011; Malow et al., 2012). Lower melatonin
sulfate excretion levels were associated with reported insomnia in
a population of 145 children and adults with ASD (Pagan et al.,
2014). However, despite a high rate of reported sleep problems in
our cohort (40%), there was no association found with melatonin
sulfate excretion rates. This might be due to exclusion from study
participation of individuals who were currently taking melatonin.
Our rates of reported sleep problems were similar to those in
unrestricted ASD populations (Sikora et al., 2012) but lower than
those reported in the AGRE cohort (55.5%) and SSC (72.5%)
(Aldinger et al., 2015).
Our study had several limitations. As this was a pilot
demonstration study evaluating the feasibility of collecting data
during specialty clinical visits, we did not have a control
group. However, our primary intent was to examine whether
and how individual biomarkers were inter-related within
this clinical ASD population. Recruitment was solely from
subspecialty tertiary care clinics. Our sample, however, was
representative of the general population of individuals with
ASD with regard to biomarker values and symptom severity.
In addition, we view the direct integration of the research
study within clinical visits as a strength that demonstrates the
feasibility of the model.
The average income of our participants, as estimated by their
home zip codes, is above the national average, and none of
our participants were in the lowest national income quintile.
However, the income ranges for participants are in line with
the region surrounding all five clinical sites (U.S. Department of
Commerce, 2013). We note that 11% of our participants endorsed
more than one race. Given changing national demographics,
it will become ever more important to consider how to best
categorize and analyze data with respect to race and ethnicity.
We relied on expert clinician determination of ASD diagnosis,
and parent report of behavioral function and comorbid medical
and psychiatric symptoms. Cognitive data were historical,
utilized a variety of measures, and were not concurrent with
biomarker collection. In addition, availability of cognitive
evaluation data, age at evaluation, and timing relative to this
study varied across subjects (Sices et al., 2017).
Diet can affect both platelet serotonin and melatonin
levels; however, dietary histories were not obtained. We also
did not evaluate complete Tanner Staging or blood work
to assess pubertal stage. Exclusion of individuals taking
medications/supplements that could influence serotonin or
melatonin levels likely reduced participation from some
individuals with disruptive behavior, anxiety, and sleep problems.
The sample size, in combination with missing data for some
variables, limited our power to identify smaller correlations.
In the future, the use of clinical registries across multiple
sites would facilitate systematic and consistent collection
of data and tracking of outcomes for larger samples. Due
to the exploratory nature of our study we did not correct
for multiple comparisons, which increased the risk of Type
I errors. Power was also impacted by the heterogeneity
of the population sample. Future studies may need to
look at subgroups of patients with particular symptom
presentations or enriched samples to improve the ability to
identify relationships.
This study examined potential correlations among biomarkers
gathered during or in association with ASD specialty clinic visits.
We found interesting potential correlations between biochemical
markers, SES, and neurologic and GI symptoms that may be
further explored in future studies. This translational research
model has promise for defining subgroups of patients based on
biomarker profiles and can help guide future studies on the use of
biomarkers for individualized prognosis and treatment planning
in individuals with complex, heterogeneous neurodevelopmental
disorders such as ASD.
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